Sensei Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Sensei Biotherapeutics's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-18.9%
Earnings growth rate
100.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -52.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Revenue & Expenses BreakdownBeta
How Sensei Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -34 | 19 | 18 |
| 30 Sep 23 | 0 | -39 | 20 | 20 |
| 30 Jun 23 | 0 | -45 | 21 | 26 |
| 31 Mar 23 | 0 | -46 | 20 | 27 |
| 31 Dec 22 | 0 | -49 | 20 | 30 |
| 30 Sep 22 | 0 | -46 | 18 | 29 |
| 30 Jun 22 | 0 | -42 | 17 | 26 |
| 31 Mar 22 | 0 | -41 | 16 | 26 |
| 31 Dec 21 | 0 | -37 | 16 | 22 |
| 30 Sep 21 | 0 | -33 | 15 | 18 |
| 30 Jun 21 | 0 | -28 | 13 | 15 |
| 31 Mar 21 | 0 | -23 | 10 | 12 |
| 31 Dec 20 | 0 | -20 | 8 | 11 |
| 30 Sep 20 | 0 | -23 | 6 | 11 |
| 31 Dec 19 | 0 | -21 | 4 | 8 |
Quality Earnings: SNSE is currently unprofitable.
Growing Profit Margin: SNSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNSE is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare SNSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: SNSE has a negative Return on Equity (-52.55%), as it is currently unprofitable.